Skip to content
Abierto
Menu

Award notice

Development of CD388 as a long-lasting prophylactic anti-viral option for protection against the health impacts caused by influenza

75A50125C00017

Office of Assistant Secretary for Preparedness and Response, Barda - Aspr / Daappo / Barda DCMA. Research and Development in Biotechnology (except Nanobiotechnology).

View on SAM.govMarkdown

Awarded

Cidara Therapeutics Inc.

$339,189,481.00 on the award notice, September 30, 2025, contract 75A50125C00017

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Cidara Therapeutics Inc.
UEI
FKP3JZ9RUNY9
CAGE
7A5L2
Vendor location
San Diego, CA
Contract
75A50125C00017, definitive contract
Obligated
$58,051,983.00, potential $339,189,481
Actions
2 between September 30, 2025 and June 2, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Development of CD388 as a Long-Lasting Prophylactic Anti-Viral Option for Protection Against the Health Impacts Caused by Influenza
Match
award number 75A50125C00017 equals the contract number; same awarding office 75A501 (high confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. October 14, 2025

    Award notice, originally solicitation

    Awarded to CIDARA THERAPEUTICS Inc. San Diego for $339,189,481. SAM.gov, notice 0e9dadb61bd9407988920c7bec1d1324

Points of contact

Also open from this buyer